1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. NEOVACS
  6. Summary
    ALNEV   FR00140077X1

NEOVACS

(ALNEV)
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
0.2384(c) 0.2254(c) 0.2168(c) 0.211(c) 0.2119(c) Last
146 508 213 513 387 213 115 101 228 432 Volume
-2.30% -5.45% -3.82% -2.68% +0.43% Change
More quotes
Estimated financial data (e)
Sales 2019
Net income 2019
Net Debt 2019
P/E ratio 2019
Yield 2019
Sales 2020 0,03 M 0,03 M 0,03 M
Net income 2020 -6,14 M -6,48 M -6,48 M
Net cash position 2020 9,68 M 10,2 M 10,2 M
P/E ratio 2020 -3,31x
Yield 2020 -
Capitalization 0,42 M 0,45 M 0,45 M
EV / Sales 2019
EV / Sales 2020 -137x
Nbr of Employees 18
Free-Float 100,0%
More Financials
Company
NEOVACS has become a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. With its innovative technology inducing a polyclonal immune response, protected by four patent families potentially until 2038, NEOVACS focuses its clinical efforts on the development of IFN?-Kinoid for treating lupus. The group also carries out preclinical work on other therapeutic vaccines... 
More about the company
All news about NEOVACS
05/02Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/03NETRI announced that it has received €8 million in funding from Neovacs S.A., and ..
CI
02/09Medical Devices Venture S.A. announced that it has received €2.3 million in fundin..
CI
02/08Medical Devices Venture S.A. announced that it expects to receive €2.3 million in ..
CI
02/01NEOVACS S.A. : REVERSE SPLIT: 1 of 10000
FA
2021NEOVACS : Monthly statement on outstanding equity shares and voting rights
CO
2021GLOBAL MARKETS LIVE : Hermès, Walt Disney, Apple, Novartis, Square...
2021GLOBAL MARKETS LIVE : Merck, Volkswagen, Salesforce, Roche, Mondelez...
2021GLOBAL MARKETS LIVE : Tencent, Vivo Energy, AT&T, Verizon, Petrobras...
2021Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021Signia Therapeutics SAS announced that it has received ?1.3 million in funding from Neo..
CI
2021GLOBAL MARKETS LIVE : Valneva, Glencore, Facebook, Roche, Hertz...
2021Neovacs S.A. announced that it has received €2 million in funding from L1 Capital Pty. ..
CI
2021GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
2021Bio Detection K9 announced that it has received $5 million in funding from Neovacs S.A.
CI
More news
News in other languages on NEOVACS
05/03Gros doigt et compte à rebours
05/03EN DIRECT DES MARCHES : BNP Paribas, Engie, Logitech, Norsk Hydro, Vallourec, Citigroup, A..
05/02Néovacs S.A. annonce ses résultats pour l'année complète se terminant le 31 décembre 20..
05/02NEOVACS : Changement de dimension réussi à l’issue de l’exercice 2021
04/06Dura Lex, Fed Lex
More news
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR00140077X1 | MarketScreener
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Hugo Brugière Chairman & Chief Executive Officer
Alexandre Courtoux Director-Finance & Administrative
Vincent Serra Chief Operations & Scientific Officer
Daniel Zagury Director
Jean-Jacques Bertrand Director
Sector and Competitors
1st jan.Capi. (M$)
NEOVACS-95.78%0
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418